Lymphomas expressing ALK fusion protein(s) other than NPM-ALK

Blood

Volumn 94, Issue 10, 1999, Pages 3509-3515

  Falini, Brunangelo ^a   Pulford, Karen ^b   Pucciarini, Alessandra ^b   Carbone, Antonino ^b   De Wolf Peeters, Chris ^b   Cordell, Jacqueline ^b   Fizzotti, Marco ^b   Santucci, Antonella ^b   Pelicci, Pier Giuseppe ^b   Pileri, Stefano ^b   Campo, Elias ^b   Ott, German ^b   Delsol, Georges ^b   Mason, David Y ^b  

^a Istituto di Ematologia   (Italy)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANAPLASTIC LYMPHOMA KINASE; HYBRID PROTEIN; PHOSPHOTRANSFERASE; UNCLASSIFIED DRUG;

ARTICLE; CELL NUCLEUS; CHROMOSOME TRANSLOCATION 2; CHROMOSOME TRANSLOCATION 5; CLINICAL ARTICLE; CLINICAL FEATURE; CONTROLLED STUDY; CYTOPLASM; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LARGE CELL LYMPHOMA; MALE; PRIORITY JOURNAL; PROGNOSIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

ADOLESCENT; HUMANS; IN SITU HYBRIDIZATION, FLUORESCENCE; LYMPHOMA; MALE; PROTEIN-TYROSINE KINASES; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; TRANSLOCATION, GENETIC;

EID: 0033570945     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (46)

1. Benharroch D, Meguerian-Bedoyan Z, Lamant L, Amin C, Brugieres L, Tenier-Lacombe MJ, Haralambieva E, Pulford K, Pileri S, Morris S, Mason DY, Delsol G: ALK-positive lymphoma: A single disease with a broad spectrum of morphology. Blood 91:2076, 1998
2. Falini B, Bigema B, Fizzotti M, Pulford K, Pileri SA, Delsol G, Carbone A, Paulli M, Magrini U, Menestrina F, Giardini R, Pilotti S, Mezzelani A, Ugolini B, Billi M, Pucciarini A, Pacini R, Pelicci PG, Flenghi L: ALK expression defines a distinct group of T/null lymphomas ("ALK lymphomas") with a wide morphological spectrum. Am J Pathol 153:875, 1998
3. Stein H, Mason DY, Gerdes J, O'Connor N, Wainscoat J, Pallesen G, Gatter K, Falini B, Delsol G, Lemke H, Schwarting R, Lennert K: The expression of Hodgkin's disease-associated antigen Ki-1 in reactive and neoplastic lymphoid tissues: Evidence that Sternberg-Reed cells and histiocytic malignancies are derived from activated lymphoid cells. Blood 66:848, 1985
4. Kadin ME: Primary Ki-1 positive anaplastic large cell lymphoma: A distinct clinicopathologic entity. Ann Oncol 5:25, 1994
5. Harris NL, Jaffe ES, Stein H, Banks P, Chan JKC, Cleary ML, Delsol G, De Wolf-Peeters C, Falini B, Gatter KC, Grogan TM, Isaacson PG, Knowles DM, Mason DY, Müller-Hermelink HK, Pileri SA, Ralfkier E, Warnke RA: A Revised European-American classification of lymphoid neoplasms: A proposal from the International Lymphoma Study Group. Blood 84:1361, 1994
6. Falini B, Pileri S, Pizzolo G, Durkop H, Flenghi L, Stirpe F, Martelli MF, Stein H: CD30 (Ki-1) molecule: A new cytokine receptor of the tumor necrosis factor receptor superfamily as a tool for diagnosis and immunotherapy. Blood 85:1, 1995
7. Zinzani PL, Bendandi M, Martelli M, Falini B, Sabattini E, Amadori S, Gherlinzoni F, Martelli MF, Mandelli F, Tura S, Pileri S: Anaplastic large cell lymphoma: Clinical and prognostic evaluation of 90 adult patients. J Clin Oncol 14:955, 1996
8. The non-Hodgkin's Lymphoma Classification Project: A clinical evaluation of the International Lymphoma Study Group classification of non-Hodgkin's lymphoma. Blood 89:3909, 1997
9. Tilly H, Gaulard P, Lepage E, Dumontet C, Diebold J, Plantier I, Berger F, Symann M, Petrella T, Lederlin P, Brière J, for the Groupe d'Etudes des Lymphomes de l'Adulte: Primary anaplastic large-cell lymphoma in adults: Clinical presentation, immunophenotype, and outcome. Blood 90:3727, 1997
10. Pileri S, Falini B, Delsol G, Stein H, Baglioni P, Poggi S, Martelli MF, Rivano MT, Mason DY, Stansfeld AG: Lymphohistiocytic T-cell lymphoma (anaplastic large cell lymphoma CD30+/Ki-1 +) with a high content of reactive histiocytes. Histopathology 16:383, 1990
11. Pileri SA, Mason DY, Mori S, Pulford K, Sabattini E, Roncador G, Piccaluga PP, Stein H, Falini B: Frequent expression of the p80 NPM-ALK chimeric fusion protein in anaplastic large cell lymphoma, lympho-histiocytic type. Am J Pathol 150:1207, 1997
12. Kinney MC, Collins RD, Greer JP, Whitlock JA, Sioutos N, Kadin ME: A small cell-predominant variant of primary Ki-1 (CD30)+ T-cell lymphoma. Am J Surg Pathol 17:859, 1993
13. Kadin ME: Anaplastic large cell lymphoma and its morphological variants. Cancer Surv 30:77, 1997
14. Shiota M, Nakamura S, Ichinohasama R, Abe M, Akagi T, Takeshita M, Mori N, Fujimoto J, Miyauchi J, Mikata A, Nanba K, Takami T, Yamabe H, Takano Y, Izumo T, Nagatani T, Mohri N, Nasu K, Satoh H, Katano H, Fujimoto J, Yamamoto T, Mori S: Anaplastic large cell lymphomas expressing the novel chimeric protein p80NPM/ALK: A distinct clinicopathologic entity. Blood 86:1954, 1995
15. Nakamura S, Shiota M, Nakagawa A, Yatabe Y, Kojima M, Motoori T, Suzuki R, Kagami Y, Ogura M, Morishima Y, Mizoguchi Y, Okamoto M, Seto M, Koshikawa T, Mori S, Suchi T: Anaplastic large cell lymphoma: A distinct molecular pathologic entity: A reappraisal with special reference to p80(NPM/ALK) expression. Am J Surg Pathol 21:1420, 1997
16. Falini B, Pileri S, Zinzani PL, Carbone A, Zagonel V, Wolf-Peeters C, Verhoef G, Menestrina F, Todeschini G, Paulli M, Lazzarino M, Giardini R, Aiello A, Foss HD, Araujo I, Fizzotti M, Pelicci PG, Flenghi L, Martelli MF, Santucci A: ALK-positive lymphoma: Clinicopathological findings and outcome. Blood 93.2697,1999
17. Mason DY, Bastard C, Rimokh R, Dastugue N, Huret J-L, Kristoffersson U, Magaud J-P, Nezelof C, Tilly H, Vannier J-P, Hemet J, Warnke R: CD30-positive large cell lymphomas (Ki-1 lymphoma) are associated with a chromosomal translocation involving 5q35. Br J Haematol 74:161, 1990
18. Morris SW, Kirstein MN, Valentine MB, Dittmer KG, Shapiro DN, Saltman DL, Look AT: Fusion of a kinase gene, ALK, to a nucleolar protein gene, NPM, in non-Hodgkin's lymphoma. Science 263:1281, 1994
19. Ladanyi M: The NPM/ALK gene fusion in the pathogenesis of anaplastic large cell lymphoma. Cancer Surv 30:59, 1997
20. Shiota M, Fujimoto J, Semba T, Satoh H, Yamamoto T, Mori S: Hyperphosphorylation of a novel 80 kDa protein-tyrosine kinase similar to Ltk in a human Ki-1 lymphoma cell line, AMS3. Oncogene 9:1567, 1994
21. Morris SW, Naeve C, Mathew P, Kirstein MN, Cui X, Witte DP: ALK, the chromosome 2 gene locus altered by the t(2;5) in non-Hodgkin's lymphoma, encodes a novel neural-specific receptor tyrosine kinase that is highly related to leukocyte tyrosine kinase (LTK). Oncogene 14:2175, 1997
22. Iwahara T, Fujimoto J, Wen D, Cupples R, Bucay N, Arakawa T, Mori S, Ratzkin B, Yamamoto T: Molecular characterization of ALK, a receptor tyrosine kinase expressed specifically in the nervous system. Oncogene 14:439, 1997
23. Bischof D, Pulford K, Mason DY, Morris SW: Role of nucleophosmin (NPM) portion of the non-Hodgkin's lymphoma-associated NPM-anaplastic kinase fusion protein in oncogenesis. Mol Cell Biol 17:2312, 1997
24. Kuefer MU, Look AT, Pulford K, Behm FG, Pattengale PK, Mason DY, Morris SW: Retrovirus-mediated gene transfer of NPM-ALK causes lymphoid malignancy in mice. Blood 90:2901, 1997
25. Downing J, Shurtleff S, Zielenska M, Curcio-Brint AM, Behm FG, Head DR, Sandlund JT, Weinburger D, Kossakowska AE, Thorner P, Lorenzana A, Ladanyi M, Morris S: Molecular detection of the t(2;5) translocation of non-Hodgkin's lymphoma by reverse transcriptase-polymerase chain reaction. Blood 85:3416, 1995
26. Shiota M, Fujimoto J, Takenaga M, Satoh H, Ichinohasama R, Abe M, Nakano M, Yamamoto T, Mori S: Diagnosis of t(2:5)(p23;q35)-associated Ki-1 lymphoma with immunohistochemistry. Blood 84: 3648, 1994
27. Hutchinson RE, Banki K, Shuster JJ, Barrett D, Dieck C, Berard CW, Murphy SB, Link MP, Pick TE, Laver J, Schwenn M, Mathew P, Morris SW: Use of an anti-ALK antibody in the characterization of anaplastic large-cell lymphoma of childhood. Ann Oncol 8:37, 1997
28. Pulford K, Lamant L, Morris S, Butler LH, Wood KM, Stroud D, Delsol G, Mason DY: Detection of ALK and NPM-ALK protein in normal and neoplastic cells with the monoclonal antibody ALK1. Blood 89:1394, 1997
29. Mason DY, Pulford K, Bischof D, Kuefer MU, Butler LH, Lamant L, Delsol G, Morris S: Nucleolar localization of the nucleophosmin-anaplastic lymphoma kinase tyrosine kinase is not required for malignant transformation. Cancer Res 58:1057, 1998
30. Wlodarska I, De Wolf-Peeters C, Falini B, Verhoef G, Morris SW, Hagemeijer A, Van den Berghe H: The cryptic inv(2) (p23q35) defines a new molecular genetic subtype of ALK-positive ALCL. Blood 92:2688, 1998
31. Cordell J, Pulford K, Bigerna B, Roncador G, Banham A, Colombo E, Pelicci PG, Mason DY, Falini B: Detection of normal and chimeric nucleophosmin in human cells. Blood 93:632, 1999
32. Pileri S, Roncador G, Ceccarelli C, Piccioli M, Briskomatis A, Sabattini E, Ascani S, Santini D, Piccaluga PP, Leone O, Damiani S, Ercolessi C, Sandri F, Pieri F, Leoncini L, Falini B: Antigen retrieval techniques in immunohistochemistry: Comparison of different methods. J Pathol 183:116, 1997
33. Cordell JL, Falini B, Erber WN, Ghosh AK, Abdulaziz Z, MacDonald S, Pulford KAF, Stein H, Mason DY: Immunoenzymatic labelling of monoclonal antibodies using immune complexes of alkaline phosphatase and monoclonal anti-alkaline phosphatase (APAAP complexes). J Histochem Cytochem 32:219, 1984
34. Ponder BA, Wilkinson WN: Inhibition of endogenous tissue alkaline phosphatase with the use of alkaline phosphatase conjugates in immunohistochemistry. J Histochem Cytochem 29:981, 1981
35. Lamant L, Meggetto F, Al Saati T, Brugières L, Bressac de Paillerets B, Dastague N, Bernheim A, Rubie H, Terrier-Lacombe MJ, Robert A, Brousset P, Rigal F, Schlaifer D, Shiota M, Mori S, Delsol G: High incidence of the t(2;5)(p23;q35) translocation in anaplastic large cell lymphoma and its lack of detection in Hodgkin's disease. Comparison of cytogenetic analysis, reverse transcriptase-polymerase chain reaction, and P-80 immunostaining. Blood 87:284, 1996
36. The International non-Hodgkin's Lymphoma Prognostic Factors Project: A predictive model for aggressive non-Hodgkin's lymphoma. N Engl J Med 329:987, 1993
37. Kaplan EL, Meier P: Nonparametric estimation from incomplete observations. J Am Stat Assoc 53:457, 1958
38. Mantel N: Evaluation of survival data and two new rank order statistics arising in its consideration. Cancer Chemother Rep 50:163, 1966
39. Cox DR: Regression models and life-tables (with discussion). J R Stat Soc 34:187, 1972
40. Pulford K, Falini B, Cordell J, Rosenwald A, Ott G, Muller-Hermelink H-K, MacLennan KA, Delsol G, Campo E, Mason DY: Biochemical detection of novel ALK proteins in tissue sections of anaplastic large cell lymphoma. Am J Pathol 154:1657, 1999
41. Borer RA, Lehner CF, Eppenberger HM, Nigg EA: Major nucleolar proteins shuttle between nucleus and cytoplasm. Cell 56: 379, 1989
42. Kondo T, Minamino N, Ngamura-Inoue T, Matsumoto M, Taniguchi T, Tanaka N: Identification and characterization of nucleophosmin/B23/numatrin which binds the anti-oncogenic transcription factor IRF-1 and manifests oncogenic activity. Oncogene 15:1275, 1997
43. Szebeni A, Mehrotra B, Baumann A, Adam SA, Wingfield PT, Olson MOJ: Nucleolar protein B23 stimulates nuclear import of the HIV-1 rev protein and NLS-conjugated albumin. Biochemistry 36: 3941, 1997
44. Li YP: Protein B23 is an important human factor for the nucleolar localization of the human immunodeficiency virus protein tat. J Virol 71:4098, 1997
45. Spector DL, Ochs RL, Busch H: Silver staining, immunofluorescence and immunoelectron microscopic localization of nucleolar phosphoproteins B23 and C23. Chromosoma 90:139,1984
46. Delsol G, Lamant L, Mariamè B, Pulford K, Dastugue N, Brousset P, Rigal-Huguet F, Al Saati T, Cerretti DP, Morris SW, Mason DY: A new subtype of large B-cell lymphoma expressing the ALK kinase and lacking the 2;5 translocation. Blood 89:1483, 1997